Altamira finds buyer for Zilentin inner ear unit so Swiss biotech can go all-in on RNA

In a move to become a “pure play” RNA company, Altamira Therapeutics is selling off 90% of its Zilentin subsidiary and its inner ear R&D work for the chance to make up to $55 million in biobucks.